World journal of surgical oncology · 2025
Evaluating long-term outcomes after cytoreductive surgery for colorectal peritoneal metastasis: do long survivors really exist?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
D'Annibale Giorgio, Aulicino Matteo, Abatini Carlo, Orsini Cecilia, Barberis Lorenzo, Lodoli Claudio, Halabieh Miriam Attalla El, Di Giorgio Andrea, Ferracci Federica, Calegari Maria Alessandra, Pacelli Fabio, Santullo Francesco
Аннотация
BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated improved overall survival (OS) and disease-free survival (DFS) in carefully selected patients with peritoneal metastases from colorectal cancer (CRC-PM). The primary aim of this retrospective study was to identify patients treated with CRS + HIPEC who achieved long-term survival and to analyze the factors most strongly associated with prolonged survival.
METHODS: Among those eligible for CRS + HIPEC, a group of patients with adequate follow-up was evaluated and divided into two groups: the long-term survival group (OS > 48 months) and the average-term survival group (OS < 48 months). A comparative analysis was performed between the two groups to evaluate which factors might be associated with an increased likelihood of long-term survival. Propensity score matching (PSM) was employed to homogenize patients based on peritoneal cancer index (PCI) and extensive small bowel involvement. A further analysis was conducted to assess the differences in recurrence behavior between the two groups.
RESULTS: During the study period, 116 patients underwent CRS + HIPEC. The median OS for the entire sample was 52 months. Among the 63 patients with at least 4 years of follow-up, 32 were identified as part of the average survival group (AS-G), while 31 were classified in the long-survival group (LS-G). DFS and survival after recurrence were statistically higher in the LS-G compared to the AS-G. Higher PCI, BRAF V600E mutation, right-sided primary tumor location, small bowel involvement, and mucinous histology were statistically more frequent in the AS-G compared to the LS-G. After PSM analysis, the absence of BRAF V600E mutation and the non-mucinous histology were significantly associated with long-term survival.
CONCLUSIONS: Long-term survival can potentially be achieved in patients with peritoneal metastasis from colorectal cancer (CRC) treated with CRS and HIPEC, often resulting in prolonged disease-free periods and less aggressive disease progression if recurrence occurs.
METHODS: Among those eligible for CRS + HIPEC, a group of patients with adequate follow-up was evaluated and divided into two groups: the long-term survival group (OS > 48 months) and the average-term survival group (OS < 48 months). A comparative analysis was performed between the two groups to evaluate which factors might be associated with an increased likelihood of long-term survival. Propensity score matching (PSM) was employed to homogenize patients based on peritoneal cancer index (PCI) and extensive small bowel involvement. A further analysis was conducted to assess the differences in recurrence behavior between the two groups.
RESULTS: During the study period, 116 patients underwent CRS + HIPEC. The median OS for the entire sample was 52 months. Among the 63 patients with at least 4 years of follow-up, 32 were identified as part of the average survival group (AS-G), while 31 were classified in the long-survival group (LS-G). DFS and survival after recurrence were statistically higher in the LS-G compared to the AS-G. Higher PCI, BRAF V600E mutation, right-sided primary tumor location, small bowel involvement, and mucinous histology were statistically more frequent in the AS-G compared to the LS-G. After PSM analysis, the absence of BRAF V600E mutation and the non-mucinous histology were significantly associated with long-term survival.
CONCLUSIONS: Long-term survival can potentially be achieved in patients with peritoneal metastasis from colorectal cancer (CRC) treated with CRS and HIPEC, often resulting in prolonged disease-free periods and less aggressive disease progression if recurrence occurs.
Предметные рубрики MeSH
Cytoreduction Surgical ProceduresCancer SurvivorsColorectal NeoplasmsPeritoneal NeoplasmsDisease-Free SurvivalHyperthermic Intraperitoneal ChemotherapyRetrospective StudiesPatient SelectionTime FactorsFollow-Up StudiesHumansMaleFemaleAdultMiddle AgedAgedAged, 80 and overTreatment OutcomeNeoplasm Recurrence, LocalSurvival Analysis